Boosters

Covid shots designed to protect against the omicron variant trigger a weaker immune response against the rapidly emerging BQ.1.1 subvariant than the previously dominant strain, according to a new lab study.

Scientists at the University of Texas Medical Branch, in a study published online Tuesday in Nature Medicine, found that the booster shots performed well against the BA.5 subvariant they were designed to target.

Country / Region Tags:

Global

General Topic Tags:

Problem, Solution, SitRep, or ?:

Analysis

Situation Report

Read more about Omicron boosters are weaker against BQ.1.1 subvariant that is rising in U.S., study finds
Log in or register to post comments

EU backs bivalent Covid shots, UK supports vaccinating infants over 6 months

Tue, 2022-12-06 18:52 — mike kraft

EU regulator backs bivalent COVID shots for primary vaccination The European Medicines Agency said on Tuesday its emergency task force has concluded that messenger RNA bivalent COVID-19 vaccines, targeting the original strain and the Omicron BA.4-5 subvariants, may be used in previously unvaccinated children and adults. Reuters Reuters

Country / Region Tags:

General Topic Tags:

Problem, Solution, SitRep, or ?:

Situation Report

Read more about EU backs bivalent Covid shots, UK supports vaccinating infants over 6 months
Log in or register to post comments

COVID vaccine hesitancy linked to 'nocebo' side effects--study

Tue, 2022-12-06 10:44 — mike kraft

COVID vaccine hesitancy linked to 'nocebo' side effects CIDRAP

Vaccine hesitancy about COVID-19 vaccines is a positive predictor of negative side effects with vaccination—an example of the "nocebo" effect—according to a study today in Scientific Reports.

Nocebo, a play on placebo, is a phenomenon in which people experience negative effects on health when they have negative views or expectations surrounding medical interventions.

Country / Region Tags:

General Topic Tags:

Problem, Solution, SitRep, or ?:

Analysis

Situation Report

Read more about COVID vaccine hesitancy linked to 'nocebo' side effects--study
Log in or register to post comments

Pfizer asks U.S. FDA to clear updated COVID shot for kids under 5

Mon, 2022-12-05 11:15 — mike kraft

Pfizer asks FDA to clear updated COVID shot for kids under 5 Pfizer is asking U.S. regulators to authorize its updated COVID-19 vaccine for children under age 5 — not as a booster but part of their initial shots. Children ages 6 months through 4 years already are supposed to get three extra-small doses of the original Pfizer COVID-19 vaccine — each a tenth of the amount adults receive — as their primary series. AP NEWS

...

Country / Region Tags:

General Topic Tags:

Problem, Solution, SitRep, or ?:

Situation Report

Read more about Pfizer asks U.S. FDA to clear updated COVID shot for kids under 5
Log in or register to post comments

China's disputes over Covid policies, Fauci says their vaccines are not good enough

Fri, 2022-12-02 11:17 — mike kraft

Inside China's fight over the future of zero-COVID Opinions about Xi Jinping's signature "zero-COVID" policy vary wildly across China. The debate, which has ignited several anti-lockdown protests, illustrates the difficulties facing the government in relaxing the world's most rigid COVID rules while heading off national discontent. David Stanway Reuters

Country / Region Tags:

General Topic Tags:

Problem, Solution, SitRep, or ?:

Analysis

Situation Report

Read more about China's disputes over Covid policies, Fauci says their vaccines are not good enough
Log in or register to post comments

Guide to New COVID Boosters: What We Know and Who Especially Needs One

Wed, 2022-11-30 10:03 — mike kraft

New COVID Boosters: What We Know About Them and Who Especially Needs One

...

Adults who haven't gotten the new booster yet have options: You can choose either Moderna's or Pfizer and BioNTech's bivalent formulas. Adults who don't want either might be able to get Novavax as a booster instead.

Here's what we know about the updated boosters.

...

Country / Region Tags:

General Topic Tags: